17:35 | 5 mins | Introduction
Chair: John Gribben |
|
17:40 | 15 mins | No, “Standard of Care” is not a thing of the past in CLL | Carol Moreno |
17:50 | 15 mins | Yes, “Standard of Care” is a thing of the past in CLL | Paolo Ghia |
18:05 | 15 mins | Novel Agents: No longer novel? | Steven Coutre |
18:15 | 15 mins | Panel discussion | All Faculty |
18:30 | 5 mins | Closing Remarks | |
18:35 | Adjourn |
13:45 | 4 mins | Welcome, introduction and objectives
Chair: Anna Schuh |
|
13:49 | 10 mins | A pharmacologist’s view on the rationale for using different BTK inhibitors for R/R CLL | Federico Pea |
13:59 | 10 mins | Evolving strategies with next generation BTK inhibitors as treatment for R/R CLL patients | Wojciech Jurczak |
14:09 | 12 mins | 2 Patient Case Reports in R/R CLL | Othman Al-Sawaf |
14:21 | 10 mins | Panel discussion | All Faculty |
14:31 | 14 mins | Audience Q&A | All Faculty |
14:45 | Adjourn |
17:00 | 5 mins | Welcome and introduction
Chair: Barbara Eichhorst |
|
17:05 | 15 mins | Understanding challenging molecular subtypes in CLL | Anna Schuh |
17:20 | 15 mins | Management of CLL with challenging molecular subtypes | Barbara Eichhorst |
17:35 | 15 mins | Strategies to address unmet needs in challenging molecular subtypes |
Matthew Davids |
17:50 | 10 mins | Audience Q&A / close | All speakers |
18:00 | Adjourn |
15:55 | 5 mins | Welcome, Introduction, Polling Questions
Chair: Richard Furman |
|
16:00 | 10 mins | The Current Role of BTK Inhibitors in CLL | Richard Furman |
16:10 | 35 mins | Case Discussions: Practical Guidance on Selecting BTK inhibitor Therapy in CLL | All Faculty |
16:45 | 10 mins | Summary, Final Thought, Audience Q&A | |
16:55 | Adjourn |